Purchase of Rare or Inherited Disease Test Directory testing for Welsh patients

Authority: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) (Central government)

GoodsAward procedure without prior publication of a call for competition

Sectors: Medical Devices & Pharma (33) Delivery: Wales (UKL22)

Awarded value£660,000published contract · exc. VAT

Awarded 15 May 2024no call for competition

Awarded to CeGat GmbH

What is being bought

Published requirement description

In-line with All Wales Medical genomic Service’s (AWMGS) commissioning model, AWMGS will procure from CeGaT whole exom sequencing (WES) for trio or singleton virtual panel analysis, MLPA and single gene testing for patients where this testing cannot be accessed within the NHS E laboratory network. This genetic testing will ensure equity of access to genomic testing for Welsh patients and meet their need to seek a timely genetic diagnosis for their rare or inherited disease.

CPV: Pathology dissection instruments and supplies

The lotProcurement structure

single lot · no lot value published

Lot #1NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale…

NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGS, for the supply of whole exom sequencing (WES) for trio or singleton virtual panel analysis, MLPA and single gene testing from CeGAT. The contract is estimated to commence in June 2024, for a period of two years.

Delivery: Wales

Procedure terms & legal framework

From the official record · publisher note attached

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 15 May 2024, 16:38 BST
Last source update: 15 May 2024, 16:38 BST
FTS notice number: 2024/S 000-015493
Classification (CPV): Pathology dissection instruments and supplies
Delivery area: Wales (UKL22)
Official registry OCID: ocds-h6vhtk-0459eb Find a Tender

Why no open competition: The procurement falls outside the scope of application of the directive
Published justification: All Wales Genomics Service (AWMGS) is commissioned by the NHS Wales Joint Commissioning Committee (JCC) (formally WHSSC) to provide genetic testing for Welsh patients which is equitable to the Clinical Indications stated in the NHSE Rare and Inherited Disease Test Directory. NHS E patients can currently access a range of Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) tests for rare and inherited diseases delivered from within the 7 Genomic Laboratory Hub service model. As a single service provider within Wales, there is necessarily a reliance on external services to enable delivery of the entire Test Directory.
In-house service developments are ongoing to increase the number of genetic tests delivered from within AWMGS and there are significant repatriations planned but these will not go-live until 2025 – 27 (services will be introduced over a 18–24-month basis) following completion of the GLIMS and relocation projects.
Due to a lack of testing capacity of NHS England laboratories to carry out the WGS based tests, reliance has been made on incumbent private provider CeGat. Given current organisational pressures to deliver an effective service, it has been noted that additional capacity be provided to supress demand. Equally, CeGAT have absorbed the sample courier responsibilities as part of the sample pathway, which has reduced the impact on AWMGS staffing. There have also been a number of MDT mechanisms established to ensure that reporting of patient results is consistent between AWMGS and CeGaT. This is critical to service delivery as it ensures equity for patients that are being referred to AWMGS and means that they are not at risk of receiving differing testing approaches depending on if testing was delivered in house or via an external laboratory. This level of bespoke service and customisation meeting the specification defined in the AWMGS standard operating procedures and consistent with UK best practice reporting guidelines is essential to delivering a robust and equitable, high-quality service. Given the bespoke attributes of the current contract, a direct award approach negates additional expenditure of the service and extended timelines.

Publisher note: NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=141500. (WA Ref:141500)

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £660,0001 contract exc. VAT

Contracts signed 1latest 15 May 2024

Awarded to	Value	Date	Status
CeGat GmbH	£660,000 †	—	Awarded

Contracts

Contract 015493-2024-1 · CeGat GmbH
Signed
15 May 2024
Value
£660,000
Status
active

Contracting authority & participating public bodies

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

Contracting authorityCentral GovernmentBody governed by public lawHealth 4-5 Charnwood Court,, Heol Billingsley, Parc Nantgarw, Cardiff, UK, CF15 7QZContact email, phone

Dispute resolution & review bodies

High CourtReview body LondonContact phone

Bidders & participating suppliers

1 commercial party on the notice

CeGaT GmbHAwarded supplier Paul-Ehrlich-Straße 23, Tubingen, DE1, D72076Contact phone

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.